TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18-70 years~* Nondiabetic patients~* Patients with primary glomerulonephritis~* Clinical diagnosis of membranous nephropathy, IgA nephropathy or focal segmental glomerulosclerosis confirmed by biopsy~* Glomerular filtration rate \> 30 mL/min~* Patients who did not receive Helicobacter pylori eradication therapy within the last three months before enrollment in study~Exclusion Criteria:~* Patients with secondary glomerulonephritis~* Glomerular filtration rate \< 30 mL/min~* Patients who received Helicobacter pylori eradication therapy within the last three months before enrollment in study~* Patients with a history of gastric surgery~* Patients without an informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Membranous nephropathy (Type: ACTIVE_COMPARATOR): Patients with primary membranous nephropathy diagnosed by biopsy
- IgA nephropathy (Type: ACTIVE_COMPARATOR): Patients with IgA nephropathy diagnosed by biopsy
- Focal segmental glomerulosclerosis (Type: ACTIVE_COMPARATOR): Patients with primary focal segmental glomerulosclerosis diagnosed by biopsy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: One Month Dual Antiretroviral Prophylaxis to Prevent Resistance Mutations in Mothers Exposed to Single Dose Nevirapine

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Meet all pre-entry criteria;~* Consent to participate and to be followed for the duration of the study;~* Present the following laboratory values within 14 days prior to inclusion:~  * Hemoglobin \> 8.0 mg/dl~ * Absolute neutrophil count \> 1000 cells/mm3~ * Platelets \> 100,000 cells/mm3~ * Serum creatinine \< 1.5 mg/dl (women with a serum creatinine \> 1.5 mg/dl must have a measured eight-hour urine creatinine clearance \> 70 ml/min)~ * SGPT less than 10 times the upper limit of normal~ * Amylase less than 150/L IU (this upper limit may change slightly depending on the normal range at the hospital laboratory).~Exclusion Criteria:~* Evidence of pre-existing fetal anomalies incompatible with life;~* Known hypersensitivity to any benzodiazepine or to NVP;~* Receipt of antiretroviral agent other than ZDV;~* Receipt of non-allowed concomitant treatment or contraindication to ddI~* Concurrent participation in another clinical trial;~* Women with a CD4 count \<200/µL or history of oral candidiasis if they are not receiving pneumocystis carinii pneumonia (PCP) prophylaxis~* Any other contra-indicated drugs during ZDV+ddI treatment for the mother as well as the child (Contra-indicated drugs such as gancyclovir, isoniazid, linezolid, ethambutol, rifabutin, cidofovir are not allowed during the ZDV ddI treatment after delivery in order to prevent pharmacological interactions or overlapping toxicities.)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Varenicline for Alcohol Dependence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be at least 18 years of age.~2. Have a current (past 12 months) DSM-IV-TR diagnosis of alcohol dependence.~3. Be seeking treatment for alcohol dependence and desire a reduction or cessation of drinking.~4. Be able to verbalize an understanding of the consent form, able to provide written informed consent, verbalize willingness to complete study procedures, able to understand written and oral instructions in English and able to complete the questionnaires required by the protocol.~5. Agree (if the subject is female and of child bearing potential) to use at least one of the following methods of birth control, unless she is surgically sterile, partner is surgically sterile or she is postmenopausal:~   1. oral contraceptives,~  2. contraceptive sponge,~  3. patch,~  4. double barrier (diaphragm/spermicidal or condom/spermicidal),~  5. intrauterine contraceptive system,~  6. levonorgestrel implant,~  7. medroxyprogesterone acetate contraceptive injection,~  8. complete abstinence from sexual intercourse,~  9. hormonal vaginal contraceptive ring, and/or~6. Be able to take oral medication and be willing to adhere to the medication regimen~7. Complete all assessments required at screening and baseline.~8. Provide evidence of stable residence in the last 2 months prior to randomization, have reasonable transportation arrangements to the study site, and have no plans to move within the next 3 months or unresolved legal problems. Subjects must provide contact information of someone, such as a family member, spouse, or significant other, who may be able to contact the subject in case of a missed clinic appointment.~9. Be willing to discontinue the use of nicotine replacement therapies prior to randomization and refrain from using nicotine replacement therapies during the course of the study.~10. Have a blood alcohol content (BAC) by breathalyzer equal to 0.000 when s/he signed the informed consent document.~11. Be someone who in the opinion of the investigator would be expected to complete the study protocol.~12. Agree to the schedule of visits, verbally acknowledge that s/he will be able to attend each scheduled visit, participate in phone visits and that s/he does not have any already scheduled events or a job that may interfere with study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Varenicline (Type: ACTIVE_COMPARATOR): Varenicline Tartrate
- Sugar Pill (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Modified Process Hib/Hep B Vaccine in Infants (V121-019)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy 2-month-old full term infants born to non-HBs Ag (hepatitis B virus) carrier mothers~Exclusion Criteria:~* Birth mother known to be a carrier of hepatitis B virus (HBsAg+) or known carriers ever living in close contact with the subject~* History of previous hepatitis B infection; history of vaccination with any hepatitis B vaccine~* Recent (\<72 hours) history of febrile illness (rectal temperature \>=38.1°C/\>=100.5°F)~* Known or suspected hypersensitivity to any component of RECOMBIVAXHB™ or COMVAX™ (e.g., aluminum, yeast)~* Recent administration (w/i 3 months prior to study start) of hepatitis B immune globulin (HBIg), serum immune globulin, or any other blood-derived product~* Receipt of investigational drugs or investigational vaccines within 3 months prior to study start or if planned within the study period;~* Known or suspected impairment of immunologic function or recent use (within 3 months prior to study start) of immunomodulatory medications (does not include topical and inhaled steroids);~* Any condition that, in the opinion of the investigator, might interfere with the evaluation of study objectives; or inability to comply with the study schedule and/or inability to attend all required study visits

- Gender: ALL
- Minimum Age: 40 Days
- Maximum Age: 80 Days
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Modified process Hib/Hep B vaccine
- 2 (Type: ACTIVE_COMPARATOR): COMVAX™

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nasal Versus Venous Lorazepam for Control of Acute Seizures in Children

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Children presenting convulsing to the pediatric emergency or developing seizure while in casualty~* Age 6-14 years~Exclusion Criteria:~* Known hypersensitivity to any benzodiazepine~* Child has received any parenteral anti-convulsant within 1 hr prior to enrollment~* Presence of severe cardio-respiratory compromise or cardiac arrhythmias~* Presence of upper respiratory tract infection~* Presence of basal skull fracture causing cerebro-spinal fluid (CSF) rhinorrhea

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Intra-nasal lorazepam 0.1 mg/kg (max 4 mg)
- 2 (Type: ACTIVE_COMPARATOR): Intra-venous lorazepam 0.1 mg/kg (max 4 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Extended-release Naltrexone for Alcohol Dependence in Primary Care

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Current alcohol dependence~* Age 18 or older~* English or Spanish-speaking~* Without untreated severe mental illness~* Liver enzymes (alanine aminotransferase and aspartate aminotransferase) ≤ 3x normal~* Kept 2 of last 3 clinic primary care appointments and/or has a working telephone number at which can be contacted directly~* Either a) currently abstinent (e.g., referred from an inpatient 'detox' setting) or b) with the ability, in the clinician's judgment, to achieve and maintain abstinence~* If female of child-bearing potential, must be using adequate contraception~* Able to understand study procedures~Exclusion Criteria:~* Currently opioid dependent or requiring ongoing treatment with opioids for any indication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Extended release injectable naltrexone (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MRG003 in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Willing to sign the ICF and follow the requirements specified in the protocol.~* Age: ≥18 years and ≤75 years, both genders~* Expected survival time≥12 weeks~* Phase Ia: Patients with histologically and cytologically confirmed advanced or metastatic solid tumor~* Phase Ib: Patients with histologically and cytologically confirmed EGFR-positive advanced or metastatic colorectal cancer, squamous cell carcinoma of head and neck, and nasopharyngeal carcinoma~* Subjects must have measurable lesions according to the response Evaluation Criteria In Solid Tumors（RECIST v1.1）~* ECOG performance score 0 or 1~* Acceptable liver, renal, and hematologic function~* Patients with childbearing potential must use effective contraception during the treatment and for 6 months after the last dose of treatment~Exclusion Criteria:~* History of hypersensitivity to any component of the investigational product~* Presence of central nervous system metastasis~* Prior history of other primary malignancies~* Known history of clinically significant hepatic diseases~* Evidence of active infection of human immunodeficiency virus (HIV)~* History of ophthalmic abnormalities~* Any severe or uncontrolled systemic disease judged by the investigator~* Patients with poorly controlled heart diseases~* Received radiotherapy, chemotherapy, biotherapy, immunotherapy or other anti-tumor drugs within 4 weeks prior to the first dose of study treatment~* Major surgery or surgical therapy for any cause within 4 weeks prior to the first dose of investigational drug~* Planned surgery or surgery is the best interest of patients as determined by investigator~* History of severe skin disease requiring interruption of previous EGFR targeted therapy; or chronic skin disease requiring oral or intravenous therapy~* Active concomitant diseases that might increase risks of toxicity~* Pregnancy, or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MRG003 (Type: EXPERIMENTAL): Phase Ia: MRG003 will be administrated by an IV infusion of escalating doses (0.1, 0.3, 0.6, 1.0, 2.0, 2.5, 3.0 mg/kg) on Day 1 of every 3 weeks (Q3W); Phase Ib: MRG003 will be administrated by an IV infusion of MTD/RP2D.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Double-Blind, Placebo-Controlled, Safety and Tolerability Study of ITI-214 in Patients With Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* NYHA class II-III heart failure~* Ejection fraction equal to or below 35%~* On stable heart failure drug treatment~Exclusion Criteria:~* Considered medically inappropriate for study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 10 mg ITI-214 (Type: EXPERIMENTAL): Single oral dose
- 30 mg ITI-214 (Type: EXPERIMENTAL): Single oral dose
- 75 mg - 150 mg ITI-214 (Type: EXPERIMENTAL): Single oral dose
- Placebo (Type: PLACEBO_COMPARATOR): Single oral dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Blood Pressure Lowering Ability and Safety of an Olmesartan and Amlodipine Based Treatment Regimen in Patients With Stage I and Stage II Hypertension

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females greater than or equal to 18 years of age~* Patients with a mean seated systolic blood pressure (MSSBP) greater than or equal to 140 mm Hg but less than or equal to 199 mm Hg or a mean seated diastolic blood pressure (MSDBP) greater than or equal to 90 mm Hg and less than or equal to 109 mm Hg, following a period of taking only placebo~* Patients with a mean daytime (8AM-4PM) systolic blood pressure greater than or equal to 135 mm Hg and less than or equal to 199 mm Hg and a mean daytime diastolic blood pressure less than or equal to 109 mm Hg as measured by an ambulatory blood pressure monitoring device (ABPM), after a period of taking only placebo~* If female, must have negative serum pregnancy test at screening and be either post-menopausal (greater than or equal to 1 year), had a hysterectomy or tubal ligation at least 6 months before consent or if of childbearing potential, must practice approved measures of birth control throughout study~Exclusion Criteria:~* History of stroke or transient ischemic attack (TIA) within the last one year~* History of myocardial infarction, coronary angioplasty, coronary artery bypass graft, or heart failure within the past 6 months~* Patients with secondary hypertension of any etiology, such as renal disease, pheochromocytoma, or Cushing's syndrome~* Type I diabetes. Patients with Type II diabetes on stable treatment, with fasting glucose \<160 mg/dl may enroll~* Patients with hemodynamically significant cardiac valvular disease~* Patients with clinically significant cardiac conduction defects, including second or third degree AV block, left bundle branch block, sick sinus syndrome, atrial fibrillation, atrial flutter, an accessory bypass tract, or any arrhythmia requiring medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Systolic blood pressure \>180 mmHg and/or diastolic blood pressure \>115 mmHg assessed on two successive occasions, 15 minutes apart at baseline~* Written informed consent~Exclusion Criteria:~* SBP ≤180 mmHg and/or DBP ≤115 mmHg~* Expectation that the patient will not tolerate intravenous antihypertensive therapy for at least 18 hours~* Known or suspected aortic dissection~* Administration of an agent for treating hypertension within 2 hours of clevidipine administration~* Severe hypertension known to be precipitated by use of, or withdrawal from, alcohol or illicit drugs, or intentional overdose of illicit or prescription drugs~* Positive pregnancy test~* Intolerance to calcium channel blockers~* Allergy to soybean oil or egg lecithin~* Known liver failure or cirrhosis~* Participation in clinical research studies of other investigational drugs or devices within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clevidipine (Type: EXPERIMENTAL): A patient-specific blood pressure target range (TR) of ≥20 mm Hg and ≤40 mm Hg SBP was prespecified by the investigator. Once established, clevidipine (0.5 mg/mL in 20% lipid emulsion) intravenous infusion was initiated at 2.0 mg/h and maintained for the first 3 minutes. Clevidipine was up-titrated, as tolerated by the patient, by doubling the dose every 3 minutes until the prespecified systolic blood pressure (SBP) target range was achieved and could continue to be titrated up or down to maintain the desired long-term SBP reduction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Male or female~* At least 18 years of age~* With a diagnosis of Clostridium Difficile-associated diarrhea (CDAD): first occurrence or first recurrence.~Key Exclusion Criteria:~* Concurrent life threatening condition.~* Immuno-compromised subjects, concomittant immuno-suppresive treatment.~* Concomitant antimicrobial treatment for CDAD.~* Any circumstances or conditions, which, in the opinion of the investigator, would affect full participation of the subject in the study or compliance with the protocol

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cadazolid 250 mg (Type: EXPERIMENTAL): Subjects received 250 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
- Cadazolid 500 mg (Type: EXPERIMENTAL): Subjects received 500 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
- Cadazolid 1000 mg (Type: EXPERIMENTAL): Subjects received 1000 mg of reconstituted cadazolid suspension twice daily and one placebo-matching vancomycin capsule four times daily for 10 days
- Vancomycin 125 mg (Type: ACTIVE_COMPARATOR): Subjects received one vancomycin capsule (125 mg) four times daily and reconstituted placebo-matching cadazolid suspension twice daily for 10 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Telemedicine Intervention to Improve Physical Function

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Physician diagnosis of idiopathic, typical Parkinson's disease (PD)~* At least 2 of 3 cardinal signs of PD~* Response to dopaminergic medication~Exclusion Criteria:~* Angina pectoris~* History of myocardial infarction within 6 months~* History of ventricular dysrhythmia requiring current therapy

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Structured exercise (Type: EXPERIMENTAL): Structured exercise instruction by smartphone
- lifestyle exercise (Type: ACTIVE_COMPARATOR): Lifestyle exercise program taught via smartphone

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete